Specialty code 174400000X · Greensboro, NC
NPI
1740213982
Since 2006
Specialty
Specialty code 174400000X
Code 174400000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
3300 Battleground Ave Ste 100
Greensboro, NC, 27410
Phone (336) 645-9555
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$1.9M
13,714 prescriptions
Company payments, 2025
$1,731
From 12 companies
Medicare prescription drug claims, 2024
In 2024, the drug Rupinder D Kaur prescribed most often to Medicare patients was Alprazolam, with 1,843 prescriptions and refills. In total Rupinder D Kaur wrote 13,714 Medicare prescriptions that cost $1.9M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-12-16.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Alprazolam Generic | 1,843 | 2,038 | 252 | $10K |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 1,173 | 1,249 | 152 | $52K |
| Trazodone Hcl Generic | 756 | 1,115 | 145 | $8,999 |
| Lamotrigine Generic | 655 | 1,128 | 111 | $9,586 |
| Clonazepam Generic | 600 | 642 | 82 | $5,173 |
| Bupropion Xl Bupropion Hcl | 545 | 1,039 | 116 | $12K |
| Fluoxetine Hcl Generic | 443 | 783 | 88 | $6,578 |
| Duloxetine Hcl Generic | 377 | 707 | 70 | $8,094 |
| Sertraline Hcl Generic | 365 | 572 | 67 | $3,892 |
| Zolpidem Tartrate Generic | 350 | 466 | 49 | $2,489 |
| Lorazepam Generic | 348 | 379 | 54 | $2,773 |
| Escitalopram Oxalate Generic | 333 | 524 | 61 | $3,085 |
| Desvenlafaxine Succinate Er Desvenlafaxine Succinate | 331 | 497 | 60 | $13K |
| Gabapentin Generic | 324 | 416 | 59 | $6,575 |
| Mirtazapine Generic | 273 | 406 | 42 | $2,931 |
Brand drugs: 1,314 claims; generic drugs: 12,400 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rupinder D Kaur $1,731 ($1,731 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $356.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 31 | $356 |
| Neurocrine BioSciences, Inc. NBIX | 20 | $228 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 14 | $220 |
| Alkermes, Inc. ALKS | 22 | $216 |
| Janssen Pharmaceuticals, Inc JNJ | 10 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 8 | $146 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 9 | $137 |
| Axsome Therapeutics, Inc. AXSM | 5 | $83.84 |
| Vanda Pharmaceuticals Inc. VNDA | 3 | $61.36 |
| Teva Pharmaceuticals USA, Inc. TEVA | 2 | $37.16 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.